STOCK TITAN

Relief Therapeutics Hldg Ag - RLFTF STOCK NEWS

Welcome to our dedicated page for Relief Therapeutics Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Therapeutics Hldg stock.

Company Overview

Relief Therapeutics Holding AG (symbol: RLFTF) is a commercial-stage biopharmaceutical company dedicated to developing innovative treatment options that address select specialty, unmet, and rare diseases. By leveraging proprietary platform technologies such as TEHCLO™ and Physiomimic™, Relief Therapeutics focuses on creating improved drug formulations designed to enhance efficacy, safety, and patient convenience. The company’s portfolio spans a broad range of therapeutic areas including rare metabolic disorders, rare skin diseases, and rare respiratory diseases, reflecting its commitment to filling critical treatment gaps in the market.

Core Business and Technology Platforms

At its heart, Relief Therapeutics is driven by a dual strategy. First, it maintains a suite of commercially marketed, revenue-generating products that are distributed via licensing and strategic partnerships. Second, it continues to invest in a robust clinical development pipeline comprising risk-mitigated assets. This balanced mix provides both short-term revenue and long-term growth potential. The company’s advancements in drug delivery are powered by its globally patented TEHCLO™ technology, which is applied to produce highly concentrated formulations, and its Physiomimic™ technology, which enables prolonged-release formulations that closely mimic the natural absorption profiles of proteins. These technologies play a critical role in formulating treatments that are both patient-friendly and therapeutically effective.

Innovative Clinical Programs and Pipeline

Relief Therapeutics is at the forefront of clinical innovation. One of its most notable development programs is RLF-OD032, an innovative, ready-to-use, highly concentrated liquid formulation of sapropterin dihydrochloride designed for the treatment of phenylketonuria (PKU). The formulation promises enhanced bioavailability and flexible dosing options, addressing limitations present in conventional therapies. Additionally, the company continues to rigorously evaluate its product profile through well-designed clinical studies comparing absorption profiles and pharmacokinetics, which underpin its regulatory strategies.

Another key asset is RLF-TD011, a novel stabilized hypochlorous acid solution formulated for the treatment of epidermolysis bullosa (EB). Utilizing its proprietary TEHCLO™ technology, RLF-TD011 offers a sprayable, self-administered solution that exhibits strong antimicrobial properties, aiming to accelerate wound closure and improve the overall wound healing environment by reducing pathogenic bacterial colonization without disrupting beneficial skin flora. Ongoing clinical investigations and investigator-initiated trials have generated promising data, supporting the potential of this treatment in addressing the multifaceted challenges of managing chronic wounds in EB patients.

Market Position and Competitive Landscape

Operating within the highly competitive biopharmaceutical industry, Relief Therapeutics differentiates itself through its targeted focus on rare and underserved diseases. Its strategy to blend commercially established products with an actively advancing pipeline positions the company uniquely in a market where niche treatments and highly specialized formulations are increasingly important. The emphasis on improving patient adherence—by reducing treatment volumes or enabling flexible dosing regimens—adds to its competitive edge, particularly in populations like pediatric patients where compliance is a critical factor.

Operational Excellence and Commercial Strategy

Relief Therapeutics adopts a partnership-based model for the commercialization of its legacy products, which allows the company to optimize its cost structure and allocate resources more efficiently into further research and development. Its licensing and distribution networks are crucial in extending market reach, while its focus on scalable and replicable technology platforms ensures that current and future treatments can be reliably marketed across major geographies. The company's maintained listings on the SIX Swiss Exchange, as well as being quoted on U.S. markets through OTCQB, enhance its visibility and accessibility to global investors.

Regulatory and Patent Milestones

The company has achieved key regulatory and intellectual property milestones that reinforce its innovation credentials. Successful clinical studies not only validate the efficacy and patient benefits of its formulations but also serve as critical precursors to potential regulatory submissions. Patent filings, including those covering the therapeutic uses of its unique highly pure formulations, serve to protect its intellectual property in strategic markets. This layered approach to R&D and IP management reflects a sophisticated, risk-mitigated development strategy in navigating complex regulatory landscapes.

Research and Development Focus

The R&D efforts at Relief Therapeutics are designed to refine and expand the applications of its cutting-edge technologies. Researchers continuously analyze pharmacokinetic profiles under varying conditions (fed versus fasted), with the goal of optimizing dosing regimens that offer enhanced metabolic control and improved patient compliance. Through rigorous clinical evaluation and subsequent patent protection, the company demonstrates a deep commitment to research excellence that supports sustained therapeutic innovation over the long term.

Commitment to Unmet Medical Needs

Relief Therapeutics is committed to addressing the shortcomings of current treatments for rare and specialty diseases. The company’s strategic focus on conditions such as PKU and EB underlines its dedication to improving life quality in patient groups that have historically faced significant treatment challenges. By providing innovative, patient-friendly formulations, Relief Therapeutics is striving to not only meet the market demand for effective treatments but also to set a new standard in therapeutic care for rare diseases.

Industry Keywords and Highlights

  • Biopharmaceutical Innovation
  • Specialty Therapeutics
  • Rare Diseases
  • Clinical Development
  • Drug Delivery Technology
  • Patient Compliance

Conclusion

The comprehensive approach of Relief Therapeutics—spanning innovative clinical development, strategic commercialization, and robust IP protection—establishes the company as an informed player within the biopharmaceutical landscape. Its commitment to transforming treatment paradigms for rare metabolic, skin, and respiratory diseases is supported by cutting-edge research and a deep understanding of patient needs. The company’s integrated strategy, from rigorous scientific inquiry to global partnership-based commercialization, assures stakeholders of its methodical and expertise-driven business model.

Rhea-AI Summary

Relief Therapeutics (OTCQB: RLFTF) announced a definitive agreement with two U.S. institutional investors for a private placement of 71,428,572 shares at CHF 0.21 each, anticipating gross proceeds of approximately CHF 15 million. The offering, set to close around July 28, 2021, will finance the acquisition of further assets and support milestone payments. CFO Jack Weinstein highlighted the financing's role in expanding the pipeline, particularly the development of RLF-100 amidst ongoing COVID-19 challenges. The placement shares will list on the SIX Swiss Exchange.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.96%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics announced that its U.S. partner, NRx Pharmaceuticals, has validated a commercial formulation of aviptadil for intravenous use, enabling high-volume manufacture with over a year's stability. NRx achieved a significant 30-to-50-fold increase in its manufactured lot size. This development is crucial for addressing the continued demand for effective treatments for respiratory failure amid COVID-19, especially given vaccination disparities and emerging variants. The company is optimistic about aviptadil's potential availability for critical patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.42%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics will issue 1 billion new shares from its authorized capital around July 27, 2021, as part of a strategic transformation into a diversified commercial-stage pharmaceutical company. Approximately 140 million shares will be used for the acquisition of AdVita, and about 206.8 million shares for APR. The remaining shares are reserved for future financing and corporate purposes. The acquisitions bolster Relief's pipeline, particularly its lead candidate, RLF-100, targeting respiratory deficiency due to COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
Rhea-AI Summary

Relief Therapeutics reported a significant finding from its partner, NRx Pharmaceuticals, indicating that aviptadil effectively prevents cytokine surges in critically ill COVID-19 patients. This data, derived from a U.S. Phase 2b/3 trial, has been submitted to the U.S. FDA as a supplement for Emergency Use Authorization. NRx is also addressing FDA requests for additional data on this application. Relief is focused on clinical-stage programs, with aviptadil as a lead candidate in late-stage testing against COVID-19 respiratory failure, while also expanding its pipeline through collaborations and acquisitions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.91%
Tags
covid-19
-
Rhea-AI Summary

Relief Therapeutics is collaborating with NRx Pharmaceuticals and Quantum Leap Healthcare Collaborative to treat COVID-19 patients using inhaled aviptadil in the I-SPY COVID Trial. This phase 2 trial targets those severely affected by the virus. Relief's lead candidate, RLF-100 (aviptadil), is undergoing late-stage testing for respiratory issues due to COVID-19. Recently, Relief also partnered with Acer Therapeutics to develop ACER-001, aimed at treating Urea Cycle Disorders. Relief is traded on the SIX Swiss Exchange under RLF and OTCQB as RLFTF.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
covid-19
-
Rhea-AI Summary

NRx Pharmaceuticals (Nasdaq: NRXP) announced the initiation of clinical training for ICU physicians in Georgia on using intravenous ZYESAMI™ (Aviptadil-acetate) for emergency COVID-19 treatment. Additionally, the ongoing phase 2/3 trial for inhaled ZYESAMI™ will be extended to Georgia and potentially neighboring countries. Clinical drug supplies are expected to ship within two weeks. The partnership is partially funded through Relief Therapeutics. ZYESAMI™ aims to address COVID-19-related respiratory failure by targeting cellular mechanisms affected by the virus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
Rhea-AI Summary

Relief Therapeutics announced the acquisition of APR Applied Pharma Research for CHF 21.5 million in cash and CHF 45 million in shares, with contingent payments based on milestones. This acquisition aims to diversify Relief's pipeline with commercial and clinical-stage products, enhancing its infrastructure for future launches. Relief gains access to APR's R&D expertise, which includes the marketed product Golike for PKU and the promising APR-TD011 for epidermolysis bullosa. The deal is viewed as a significant step in Relief's transformation into a robust commercial-stage biopharmaceutical firm.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
Rhea-AI Summary

Relief Therapeutics Holding AG held its Annual General Meeting (AGM) on June 20, 2021, where all agenda items were approved by over 90% of represented votes. The meeting, conducted virtually due to COVID-19, saw participation equivalent to 41.54% of total outstanding shares. Key outcomes include the approval of the 2020 financial statements, a CHF 20,009,867 loss carryforward, and increases in authorized and conditional share capital. New board members Dr. Patrice Jean and Paolo Galfetti were elected to aid in the company’s growth strategy, focusing on the development of RLF-100 and other business opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics Holding AG (OTCQB: RLFTF) reported on June 16, 2021, that its collaboration partner, NRx Pharmaceuticals, announced results from the U.S. Expanded Access Protocol (EAP) for the drug RLF-100 (aviptadil). The EAP involved 240 ICU patients with critical COVID-19 respiratory failure. NRx intends to submit these findings as "real world" evidence to the FDA, supporting earlier clinical trial results. Relief focuses on clinical-stage programs, with RLF-100 in late-stage development for COVID-19 and a collaboration for the treatment of Urea Cycle Disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
covid-19
Rhea-AI Summary

Relief Therapeutics Holding AG (OTCQB: RLFTF) has announced that NRx Pharmaceuticals submitted an application to the FDA for Emergency Use Authorization (EUA) for its drug aviptadil to treat critical COVID-19 patients with respiratory failure. The EUA submission is based on a successful phase 2b/3 clinical trial in the U.S. Relief anticipates the decision from the FDA and is optimistic about the drug's potential to provide effective treatment options. The company also acknowledges NRx's recent Nasdaq listing and aims to advance aviptadil's development in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none

FAQ

What is the current stock price of Relief Therapeutics Hldg (RLFTF)?

The current stock price of Relief Therapeutics Hldg (RLFTF) is $2.63 as of April 1, 2025.

What is the market cap of Relief Therapeutics Hldg (RLFTF)?

The market cap of Relief Therapeutics Hldg (RLFTF) is approximately 37.6M.

What is the core focus of Relief Therapeutics?

Relief Therapeutics focuses on developing innovative treatments for select specialty, unmet, and rare diseases, primarily in the areas of metabolic, skin, and respiratory disorders.

Which proprietary technologies does the company use?

The company utilizes proprietary platform technologies such as TEHCLO™ for concentrated formulations and Physiomimic™ for prolonged-release drug delivery, both designed to enhance therapeutic efficacy and patient compliance.

What are some key assets in Relief Therapeutics' pipeline?

Key assets include RLF-OD032 for the treatment of phenylketonuria (PKU) and RLF-TD011, a novel hypochlorous acid formulation for the management of epidermolysis bullosa (EB).

How does Relief Therapeutics differentiate itself in the market?

The company differentiates itself by combining a portfolio of commercially marketed products with a robust clinical development program, using innovative technologies to develop treatments that address unmet medical needs and improve patient convenience.

What strategies support its commercialization efforts?

Relief Therapeutics employs a partnership-based commercialization model, leveraging licensing and distribution agreements to maximize market reach while concentrating internal resources on research and development.

How does the company address regulatory and intellectual property challenges?

Relief Therapeutics has achieved significant regulatory milestones through positive clinical studies and strategic patent filings that protect its innovative formulations across key global markets.

What role do clinical studies play in its development strategy?

Clinical studies are critical to the company’s approach, as they validate the efficacy and safety of its innovative formulations, inform regulatory submissions, and help optimize dosing strategies to enhance patient outcomes.

Where is Relief Therapeutics listed and how does it maintain investor visibility?

The company is listed on the SIX Swiss Exchange under the symbol RLF and is quoted on U.S. markets via OTCQB, ensuring strong visibility and accessibility to global investors.
Relief Therapeutics Hldg Ag

OTC:RLFTF

RLFTF Rankings

RLFTF Stock Data

37.62M
9.57M
0.57%
23.31%
Biotechnology
Healthcare
Link
Switzerland
Geneva